Last updated 5 days ago
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
750 patients around the world
Available in Puerto Rico, Spain, United States, Argentina, Brazil
BeiGene
4Research sites
750Patients around the world
This study is for people with
Non-Hodgkin Lymphoma
Follicular lymphoma
Lymphoma
Marginal zone lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Hospital Alemán
Recruiting
Clínica Zabala Swiss Medical
Recruiting
StudyBGB-3111-308
SponsorBeiGene
Conditions
Follicular lymphomaMarginal zone lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05100862
